Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study
(2023). Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study. EKB Journal Management System, 3(2), -. doi: 10.21608/esdlj.2023.456195
. "Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study". EKB Journal Management System, 3, 2, 2023, -. doi: 10.21608/esdlj.2023.456195
(2023). 'Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study', EKB Journal Management System, 3(2), pp. -. doi: 10.21608/esdlj.2023.456195
Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study. EKB Journal Management System, 2023; 3(2): -. doi: 10.21608/esdlj.2023.456195

Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study

Egyptian Society of Diabetes and Lipidology Journal
Volume 3, Issue 2, October 2023    PDF (758.07 K)
Document Type: Abstracts
DOI: 10.21608/esdlj.2023.456195
Abstract
Patients with diabetic kidney disease (DKD) are at increased risk of developing postcontrast acute kidney injury (AKI). Diabetic patients under dipeptidyl peptidase 4 inhibitors (DPP4Is) experience a lower propensity to develop AKI. We speculated that linaglipin as a single agent or in combination with allopurinol may reduce the incidence of post-contrast AKI in stage 3–5 chronic kidney disease (CKD) patients with underlying DKD. 
Statistics
Article View: 22
PDF Download: 11